Omni Bio Pharmaceutical Inc

Omni Bio Pharmaceutical — Investor Presentation (September 2013)

24 slides from Omni Bio Pharmaceutical's investor presentation, Sep 9, 2013

  1. Slide 1: An Overview of Omni Bio Pharmaceutical, Inc.

    Slide 1: An Overview of Omni Bio Pharmaceutical, Inc.

    Exhibit 99. An Overview of Omni Bio Pharmaceutical, Inc. A Company Focused on Creating Breakthrough Therapies Bruce Schneider, Ph.D. September, 2013

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

  3. Slide 3: Quick Overview of Omni

    Slide 3: Quick Overview of Omni

    ~ Quick Overview of Omni e Public company since 2009 (symbol OMBP.OB) © Initially focused on promoting & licensing new uses of plasma-derived alpha-1 antitrypsin (p-AAT) e Now developing “Enbrel-like” recombinant Fc fusion proteins (Fc-AATs) e Multiple disease targets identified along with a potenti

  4. Slide 4: Our Team

    Slide 4: Our Team

    — = Our Team e CEO - Bruce Schneider, PhD * Over 35 years experience in drug development * Most recently EVP & Chief of Research Operations at Wyeth/Pfizer e CSO - Charles Dinarello, MD « World recognized “father” of cytokine biology * Current affiliations with Univ of Colorado and Radboud Univ (Net

  5. Slide 5: What's Plasma-derived AAT (p-AAT)?

    Slide 5: What's Plasma-derived AAT (p-AAT)?

    What's Plasma-derived AAT (p-AAT)? e Naturally occurring protease inhibitor with anti- inflammatory and tissue protective effects e Extracted and purified from whole human blood e Currently approved to treat AAT-deficient patients « Emphysema, COPD Product characteristics « 25 year safety record « I

  6. Slide 6: Key attributes of Omni's lead molecule: Recombinant AAT

    Slide 6: Key attributes of Omni's lead molecule: Recombinant AAT

    e Key attributes of Omni’s lead molecule: Recombinant AAT e 40-50x more potent than p-AAT in various eN animal models e Improved stability and longer duration of effect e Manufacturing — simpler, lower cost, no risk of viral contamination ° Safety & efficacy risk mitigated by p-AAT experience e Key

  7. Slide 7: Fc-AAT Value Creation Strategies

    Slide 7: Fc-AAT Value Creation Strategies

    EE = eee Fc-AAT Value Creation Strategies e Fast-to-Market option * Position as a “bio-similar/bio-better” product to replace p-AAT for existing emphysema indication * May only require early phase 1 work followed by a single phase 2/3 study demonstrating equivalence to existing product and lack of i

  8. Slide 8: Fc-AAT Market Opportunity

    Slide 8: Fc-AAT Market Opportunity

    -AAT Market Opp "Attractive Fast-to-Market Option Disease Market Size (US/EU) ‘AAT Replacement Therapy ~$500M. Potential First New Indications Disease Market Size (US/EU) Type 1 Diabetes (Early Onset) >S1B Graft vs Host Disease ~S500M Gout (Treatment Refractory) >$1B Options For Life Cycle Managemen

  9. Slide 9: e[opefete epefape| oleae e~efepe etetape etefale

    Slide 9: e[opefete epefape| oleae e~efepe etetape etefale

    e[opefete epefape| oleae e~efepe etetape etefale ean Et Obl Fa Ore talamctCanan ec @ | rece Po° | ED CellLine Selection SEsabisn ca ae, | | | Enrly Analyical Dew. 1 Eat Famuifen De | NP Orig Protot GD et) | NOKmbIng OPToiccooy ED FOAPreIND Mectng 1 | *Spociiciming subject o funding availabilty oS ic

  10. Slide 10: Decision Points

    Slide 10: Decision Points

    ‘Decision Points $1.5M per year needed for ongoing operating expenses $5-6M needed to complete preclinical development (now) + Process/formulation/analytical development + Ancillary pharmacology & pilot toxicology studies + GMP clinical trial material (drug product) + IND enabling animal toxicology

  11. Slide 11: Potential Fc-AAT Strategic Opportunities

    Slide 11: Potential Fc-AAT Strategic Opportunities

    Potential Fc-AAT Strategic Opportunities e Proceed with self-funded development through first patient studies then license to established pharma player « 3-4 year outlook ¢ Potential 5-10x value play; greatest funding requirement e Partner with established pharma player to fund or co- fund next deve

  12. Slide 12: Other Omni Assets

    Slide 12: Other Omni Assets

    “Other Omni Assets e Method-of-use patents for new p-AAT indications* * Diabetes mellitus * Graft vs. host disease (GvHD) and non-organ transplantation rejection « Radioprotection * Certain bacterial and viral infections « Post infarction myocardial remodeling e Secondary strategy to sub-license pat

  13. Slide 13: Licensing Being Supported: New Clinical Trials

    Slide 13: Licensing Being Supported: New Clinical Trials

    T Licensing Being New Clinical Trials e Type 1 Diabetes ¢ Three pilot studies completed (Immune Tolerance Network, Kamada, Omni) All show loss of pancreatic beta cell function (essential for insulin production) slowed/halted in certain patients e Graft vs Host Disease (GVHD) ¢ Affects ~50% of all bo

  14. Slide 14: Near-term Value Drivers for Omni

    Slide 14: Near-term Value Drivers for Omni

    Ze . = . Near-term Value Drivers for Omni e Within next 12-18 months ¢ Fc-AAT patent issuance FDA endorsement of Fc-AAT plan and orphan drug status Successful GMP manufacturing scale-up/stable RT formulation campaign Successful tox data package enabling IND/first clinical study of Fo-AAT Positive da

  15. Slide 15: Corporate Information

    Slide 15: Corporate Information

    “Corporate Information | e Stock symbol OMBP.OB ¢ Closing stock price (9/4/13) $0.20 e 52-week range $0.17-0.60 e Shares outstanding 38.2 million e Fully diluted shares 68.0 million Market capitalization (9/4/13) $7.6 million e Fiscal year-end March 31 e Cash on hand (9/4/13) $1.0 million 5 OPPniBio

  16. Slide 16: Omni Summary

    Slide 16: Omni Summary

    “Omni Summary e Our centerpiece recombinant Fc-AAT program has very broad, high value potential e Fc-AAT development plan ¢ Includes a valuable fast-to-market option ¢ Is supported by a new management team and advisors with deep experience ¢ Targets several value inflection points within next 2 year

  17. Slide 17: Appendix

    Slide 17: Appendix

    Appendix Representative Data Slides : OffriBio

  18. Slide 18: Fc-AAT Highlights - Inflammation (1)

    Slide 18: Fc-AAT Highlights - Inflammation (1)

    ~Fe-AAT Highlig hts - Inflammation A) Fc-AAT produces dose-dependent reductions in joint inflammation in gout arthritis model 26 p<0.001 Joint swelling (0-3) Co Kee Ce & << eo “4hours after chemical-induced inflammation BS OPniBio

  19. Slide 19: Fc-AAT Highlights - Inflammation (2)

    Slide 19: Fc-AAT Highlights - Inflammation (2)

    Pee 2 a Ss Fc-AAT Highlights — Inflammation (2) Fc-AAT highly effective in clearing granular infiltrates that cause inflammation in gout model Ivig 50ug AAT-Fe 50ug “4 hours after chemical-induced inflammation » OP

  20. Slide 20: Fc-AAT Highlights - Inflammation (3)

    Slide 20: Fc-AAT Highlights - Inflammation (3)

    EEE : = Fc-AAT Highlights — Inflammation (3) Fc-AAT 50 mcg at least as effective as p-AAT 2 mg and competitive with high-dose IL1-Ra (anakinra) in gout model 4. p<0.001 0001 3 =I | a re : g He i” he 0 ‘i s ” Se Oe ee a oe oo “4 hours after chemical-induced inflammation = OPniBio

  21. Slide 21: Data Highlights - Type 1 Diabetes

    Slide 21: Data Highlights - Type 1 Diabetes

    EE : eee Data Highlights — Type 1 Diabetes p-AAT treatment preserves islet cell function (essential for insulin production) Insulin Glucagon ge A Bee I : 8 i. ee Lirsuinwaat iol elf Instn Contot Bah ‘y_& we t mo am oe P-AAT Treated Days after initial therapy Clvcose normatzed wih AAT fr ne rar ageme

  22. Slide 22: Type 1 Diabetes - Pilot Study of p-AAT

    Slide 22: Type 1 Diabetes - Pilot Study of p-AAT

    EEE = : Type 1 Diabetes - C-peptide Mean 2-hour AUC (pmolimL) Pilot Study of p-AAT 8-week dosing in patients suggests stabilization of C-peptide levels 2.0 = = Pediatric 15 7 Adult ‘Mean change from baseline: 1.0 Adult: +0.013 (p=0.852) + Pediatric: 0.191 (p=0.148) 0.5 0.0 0 100 200 300 400 Study Da

  23. Slide 23: Data Highlights - Graft vs Host Disease

    Slide 23: Data Highlights - Graft vs Host Disease

    Pe = es Data Highlights — Graft vs Host Disease p-AAT reduces mortality from GvHD in mouse transplant model 100 80 = 60 ~® Matched Transplant (n=8) 3 2 “t- Mis-matched Transplant (n=9) ¢*° ~#- Mis-matched Transplant 20 + p-AAT (n=9) 0 0 10 20 30 40 50 60 70 Days after BMT Tawara | et al. PNAS 2012;1

  24. Slide 24: Data Highlights - Cardiac Re-Modeling

    Slide 24: Data Highlights - Cardiac Re-Modeling

    AS . . aF . Data Highlights - Cardiac Re-Modeling p-AAT reduces acute myocardial infarct size in mouse model Albumin AAT Infarct Infarct N=6 pergroup * P<0.05vs sham ** P<0.05 vs Albumin ‘Toldo eta. (2011) J Mol Cell Cardio 512): 244-51 “4 OPniBio

Source: SEC EDGAR · 8-K filed Sep 9, 2013

More decks from Omni Bio Pharmaceutical Inc